# Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

> **NCT00940316** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 28 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** panitumumab
- **DRUG:** erlotinib hydrochloride
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00940316
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-18
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00940316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00940316, "Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00940316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*